SAN FRANCISCO, Feb. 14, 2023 /PRNewswire/ -- The global regenerative medicine market size is expected to reach USD 180.87 billion by 2030 expanding at a CAGR of 15.7% from 2023 to 2030, according to a new report by Grand View Research, Inc., The presence of a strong pipeline is one of the major drivers in the regenerative medicine market. Companies invest heavily in R&D to upgrade their products with the latest technology and fulfil the unmet needs of their customers.
Key Industry Insights & Findings from the report:
- The therapeutics segment held the largest share in the regenerative medicine market, owing to the growing aging population coupled with an increasing rate of age-related disorders.
- The rise in a number of clinical trials for stem cell and tissue-based regenerative therapies along with an increase in demand for regenerative therapies is expected to positively influence the growth of the market.
- Stem cell and progenitor cell-based therapies are projected to witness significant growth owing to huge investments in the R&D space and a growing number of stem cell banks.
- North America dominated the market in 2022 owing to the presence of a significant number of research organizations and universities which are working on R&D of stem cell-based therapies.
- Asia Pacific is anticipated to witness the fastest growth in the coming years owing to the rapid adoption of cell-based methods in the healthcare industry.
- By therapeutic category, the oncology segment dominated the segment in 2022 owing to the increasing cases of cancer globally which is rising the demand for better solutions. The growing number of robust pipelines is driving the market growth.
Read 180-page full market research report, "Regenerative Medicine Market Size, Share & Trends Analysis Report By Product (Cell-based Immunotherapies, Gene Therapies), By Therapeutic Category, By Region, And Segment Forecasts, 2023 - 2030", published by Grand View Research.
Regenerative Medicine Market Growth & Trends
Furthermore, with the increasing demand for disease treatment therapies, companies have focused their efforts to accelerate R&D for gene therapies that target the cause of disease at a genomic level. The cell and gene therapies in the U.S. pipeline programs (Phase I-III trials) grew from 289 in 2018 to 362 by 2019 according to the data published by PhRMA, This represents an increase of 25% in a single year. Continuous advancements in this field would further boost the demand for regenerative medicines.
Technological advancements such as stem cells, tissue engineering, and nanotechnology has made regenerative medicines a highly interdisciplinary in field. Stem cells are undifferentiated cells, which have the capability to repair and/or regenerate into other cells such as cartilage, tendons, ligaments, muscle, and bones. In July 2021, BlueRock Therapeutics received FDA approval for its pluripotent stem cell-derived dopaminergic neuron therapy, DA01, for advanced Parkinson's disease treatment. This approval was expected to expand the company's offerings.
Several key players are taking strategic initiatives such as new product development, strategic alliances, and others have contributed to the regenerative medicine market growth. For instance, in November 2021, Astellas Pharma, Inc. entered into an agreement with Pantherna Therapeutics GmbH to study mRNA-based regenerative medicine. Under this initiative, Astellas' high drug discovery capabilities and Pantherna's state-of-the-art mRNA platform will be used to promote research on developing a new program. In addition, in May 2021, Bayer AG entered into a collaboration with Senti Bio for gene circuit-engineered cell therapies development for regenerative medicine.
Regenerative Medicine Market Segmentation
Grand View Research has segmented the regenerative medicine market report based on product, therapeutic category, and region
Regenerative Medicine Market - Product Outlook (Revenue, USD Million, 2018 - 2030)
- Therapeutics
- Primary cell-based therapeutics
- Dermatology
- Musculoskeletal
- Surgical
- Dental
- Others
- Stem Cell & Progenitor Cell-based therapeutics
- Autologous
- Allogenic
- Others
- Cell-based Immunotherapies
- Gene Therapies
- Tools
- Banks
- Services
Regenerative Medicine Market - Therapeutic Category Outlook (Revenue, USD Million, 2018 - 2030)
- Dermatology
- Musculoskeletal
- Immunology & Inflammation
- Oncology
- Cardiovascular
- Ophthalmology
- Others
Regenerative Medicine Market - Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Thailand
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
List of Key Players of Regenerative Medicine Market
- AstraZeneca plc
- F. Hoffmann-La Roche Ltd.
- Integra Lifesciences Corp.
- Astellas Pharma, Inc.
- Cook Biotech, Inc.
- Bayer AG
- Pfizer, Inc.
- Merck KGaA
- Abbott
- Vericel Corp.
- Novartis AG
- GlaxoSmithKline (GSK)
- Baxter International, Inc.
- Boehringer Ingelheim
- Amgen Inc.
- Cesca Therapeutics, Inc.
- U.S. Stem Cell, Inc.
- Bristol-Myers Squibb
- Eli Lilly and Company
- NuVasive, Inc.
- Organogenesis, Inc.
- MiMedx Group, Inc.
- Takara Bio, Inc.
- Osiris Therapeutics, Inc.
- Corline Biomedical AB
Check out more related studies published by Grand View Research:
- Induced Pluripotent Stem Cells Production Market - The global induced pluripotent stem cells production market size is estimated to reach USD 2.8 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 9.2% from 2022 to 2030. The increase in demand for induced pluripotent stem cells (iPSCs) in comparison to Embryonic Stem Cells (ESCs) has offered a significant drive to the market. Advantages such as no stem cell-related ethical issues, personalized treatment, and flexibility during cell-based research have created a favorable scenario for market growth. In addition, the prevalence of chronic disorders is also driving the growth of the induced pluripotent stem cells production market, as conditions like heart disease, stroke, diabetes, and many more can be treated by utilizing iPSCs-mediated therapy. For example, according to the International Diabetes Federation (IDF), 537 million people are already living with diabetes in 2021.
- Microcarriers Market - The global microcarriers market size is estimated to reach USD 3.2 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 11.6% from 2022 to 2030. The growth of the market is driven by the rising demand of cell-cultured products, the growing burden of diseases worldwide, constant investments for intensive R&D activities to identify and develop new treatments for rare disorders, and the continuous developments in technologies employed in advanced research such as cell-biology.
- Biopreservation Market - The global bio preservation market size is projected to reach USD 16.61 billion by 2030, registering a CAGR of 28.9% from 2022 to 2030, according to a new report by Grand View Research, Inc. The extensive use of preservation in hospitals and labs, rising funding assistance from government and private partners in healthcare, and an upsurge in research and development are fueling the industry growth.
Browse through Grand View Research's Biotechnology Industry Research Reports.
About Grand View Research
Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Web: https://www.grandviewresearch.com
Grand View Compass | Astra ESG Solutions
Follow Us: LinkedIn | Twitter
Logo: https://mma.prnewswire.com/media/661327/Grand_View_Research_Logo.jpg

Share this article